Decheng Capital LLC Acquires New Holdings in Aardvark Therapeutics, Inc. (NASDAQ:AARD)

Key Points

• Decheng Capital LLC acquired 3,917,299 shares of Aardvark Therapeutics, valued at approximately $29.4 million, making it the firm's 3rd largest holding.
• Aardvark's stock has shown significant volatility, with a one-year range of $4.88 to $19.58, currently trading at $12.69.
• Analyst ratings for Aardvark Therapeutics are mixed, with one "sell" rating, five "buy" ratings, and an average price target of $33.00.

Decheng Capital LLC acquired a new stake in shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,917,299 shares of the company's stock, valued at approximately $29,419,000. Aardvark Therapeutics makes up 8.3% of Decheng Capital LLC's investment portfolio, making the stock its 3rd largest holding. Decheng Capital LLC owned approximately 18.06% of Aardvark Therapeutics at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AARD shares. HC Wainwright started coverage on shares of Aardvark Therapeutics in a report on Monday, June 30th. They issued a "buy" rating and a $40.00 price target for the company. Royal Bank Of Canada lowered their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Finally, Wall Street Zen downgraded shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Aardvark Therapeutics has an average rating of "Moderate Buy" and an average target price of $33.00.

Aardvark Therapeutics Price Performance

NASDAQ AARD traded up $0.12 during trading on Friday, hitting $12.13. The stock had a trading volume of 36,180 shares, compared to its average volume of 89,302. Aardvark Therapeutics, Inc. has a one year low of $4.88 and a one year high of $19.58. The firm's 50 day moving average price is $12.34.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

Aardvark Therapeutics Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.